AITC for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: Allyl Isothiocyanate, Oil of Mustard, AIT, 2-Propenyl Isothiocyanate, Volatile Mustard Oil

Motivation

Allyl isothiocyanate (AITC) is the small natural compound responsible for the sharp pungency of mustard, horseradish, and wasabi. It is released when chewing or grating breaks open cruciferous plant tissue, where a precursor meets a plant enzyme to form the active compound. AITC belongs to the same family of dietary protective compounds as the much-studied broccoli compound. Its near-complete absorption from food and striking tendency to concentrate in the bladder set it apart from related plant compounds.

Centuries of culinary and traditional medicinal use are matched by a substantial laboratory research record. Cell and animal studies have explored AITC for bladder cancer prevention and broad antimicrobial activity, with the most clinically translated application being a German herbal preparation used for respiratory and urinary tract infections. Recent work also points to a role in cardiac aging via parasympathetic nervous system tone. Yet human evidence for health outcomes remains limited, and what exists has so far failed to reproduce the metabolic effects seen in animals.

This review examines what is currently known about AITC across its proposed health and longevity applications, where evidence is strongest, where it remains speculative, and what the gap between animal and human findings means for dietary use.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Allyl Isothiocyanate

The Grokipedia entry covers AITC’s chemistry and physical properties, biosynthesis from sinigrin via myrosinase, antimicrobial and fumigant uses, sensory mechanisms via TRPA1 (transient receptor potential ankyrin 1, a sensory ion channel that detects noxious stimuli) and TRPV1 (transient receptor potential vanilloid 1, a channel that detects heat and pungency) activation, toxicology including the rat oral LD50 (the dose lethal to 50% of test animals), and ongoing research into its anticancer and anti-inflammatory potential — providing a broad scientific context for the compound’s biological activity.

Examine

No dedicated Examine.com article for AITC was found. Examine.com covers the structurally related sulforaphane extensively but has not published a dedicated page for allyl isothiocyanate.

ConsumerLab

No dedicated ConsumerLab article for AITC was found. While mustard-containing products and cruciferous vegetable supplements are commercially available, ConsumerLab has not published a review focused specifically on AITC.

Systematic Reviews

No systematic reviews or meta-analyses for AITC were found on PubMed as of 05/02/2026.

Mechanism of Action

AITC exerts its biological effects through several interconnected pathways:

Nrf2/Keap1 activation: AITC modifies cysteine residues on Keap1, enabling Nrf2 translocation to the nucleus and induction of phase II detoxification enzymes including glutathione S-transferases (enzymes that conjugate toxic compounds with glutathione for elimination) and UDP-glucuronosyltransferases (enzymes that attach glucuronic acid to toxins to make them water-soluble for excretion).
NF-κB suppression: AITC inhibits activation of NF-κB, reducing production of pro-inflammatory cytokines including TNF-alpha (tumor necrosis factor alpha, a key inflammatory signaling protein) and IL-6 (interleukin-6, an inflammatory cytokine), and suppressing iNOS (inducible nitric oxide synthase, an enzyme that produces large amounts of nitric oxide during inflammation) and COX-2 (cyclooxygenase-2, an enzyme that generates pro-inflammatory prostaglandins) expression.
TRPA1 channel activation: AITC is a potent and selective agonist of TRPA1, expressed in sensory neurons, vagal afferents, and other tissues. TRPA1 activation in cardiac vagal afferents reflexively enhances parasympathetic tone, which is implicated in cardiac homeostasis and the recently reported cardiac longevity signal in heart tissue.
Apoptosis induction via reactive oxygen species (ROS): AITC triggers mitochondria-mediated apoptosis (programmed cell death) by elevating intracellular ROS (reactive oxygen species, chemically reactive molecules that at high levels can trigger cell death), depolarizing the mitochondrial membrane, and activating caspase-9 and caspase-3 (enzymes that execute the cell-death cascade) — a mechanism with implications for cancer chemoprevention.
Cell-cycle arrest: AITC induces G2/M (growth phase 2 to mitosis) checkpoint arrest by modulating Wee1 (a kinase that prevents premature entry into mitosis), Chk1 (checkpoint kinase 1, an enzyme that halts cell division when DNA damage is detected), and CDK1 (cyclin-dependent kinase 1, an enzyme essential for initiating cell division)/cyclin B signaling in proliferating cells.
Antimicrobial action: AITC disrupts microbial cell membranes, inhibits bacterial enzyme systems by reacting with cysteine residues, and impairs biofilm formation, producing broad-spectrum activity against gram-positive bacteria, gram-negative bacteria, fungi, and parasites.

Pharmacological properties: AITC is a small (molecular weight 99.16 g/mol) volatile liquid with very high oral bioavailability (~90%). Its biological half-life is short — peak plasma and urinary metabolite concentrations occur within hours after oral intake. Tissue distribution is highly skewed: urinary metabolite concentrations are at least 10-fold higher than plasma, and bladder tissue concentrations after oral dosing in rats are 14–79 times higher than in other organs. AITC is metabolized primarily through the mercapturic acid pathway, conjugated with glutathione by glutathione S-transferases and excreted in urine predominantly as N-acetyl-S-(N-allylthiocarbamoyl)-L-cysteine (NAC-AITC).

Historical Context & Evolution

Allyl isothiocyanate has been recognized as the pungent principle of mustard and horseradish for centuries. Mustard has been used medicinally since ancient times — Hippocrates documented mustard plasters for pain relief, and traditional applications included topical poultices for respiratory complaints and rheumatic pain, and culinary use as a digestive stimulant. The sharp, sinus-clearing sensation of wasabi and horseradish has been a part of Japanese and European culinary traditions for hundreds of years.

Modern scientific interest in AITC began in the 1990s, in parallel with the broader investigation of cruciferous vegetable isothiocyanates that followed Paul Talalay’s discovery of sulforaphane’s chemoprotective properties at Johns Hopkins. Yuesheng Zhang’s laboratory at Roswell Park Cancer Institute attracted attention to AITC by establishing its exceptionally high oral bioavailability (~90%) and the unusual pharmacokinetic property of preferential urinary bladder accumulation, making it a strong candidate for bladder cancer chemoprevention. Subsequent work confirmed AITC’s anticancer activity in orthotopic rat bladder cancer models and demonstrated synergistic activity with COX-2 inhibitors.

A new dimension opened in 2025, when a GeroScience study from Michigan State University reported that long-term dietary AITC ameliorates cardiac fibrosis and diastolic dysfunction in aged mice through TRPA1 activation, with measurable increases in heart rate variability and parasympathetic index. AITC retains GRAS (Generally Recognized As Safe) status in the United States and is approved as a food flavoring agent. No standalone AITC supplements are marketed for health outcomes; clinical development for therapeutic indications remains in early stages, anchored mainly by the AITC-containing herbal preparation Angocin in Germany.

Expected Benefits

Medium 🟩 🟩

Bladder-Selective Cancer Chemoprevention

AITC exhibits bladder-selective cancer chemopreventive activity rooted in its pharmacokinetic profile: urinary metabolite concentrations are at least 10× higher than plasma, and bladder tissue concentrations are 14–79× higher than in other organs after oral dosing. In orthotopic rat bladder cancer models, low oral doses (~1 mg/kg) significantly inhibited both tumor development and muscle-invasive progression, and combination with the COX-2 inhibitor celecoxib produced enhanced inhibition. The evidence base is preclinical: multiple in vivo rat studies, the Zhang (2010) review, and the Bhattacharya et al. (2013) combination study. Human efficacy data are absent, so the ceiling on this evidence remains animal models with strong mechanistic and pharmacokinetic rationale.

Magnitude: ~50–65% inhibition of bladder cancer growth in rat orthotopic models at ~1 mg/kg oral dosing. Bladder tissue concentrations 14–79× higher than other organs. No human efficacy data.

Antimicrobial Activity

AITC displays broad-spectrum antimicrobial activity against gram-positive bacteria (Staphylococcus aureus, Listeria monocytogenes), gram-negative bacteria (Escherichia coli, Salmonella), fungi (Aspergillus, Penicillium), and several parasites. The clinically most translatable evidence comes from the AITC-containing herbal preparation Angocin Anti-Infekt N, authorized in Germany for inflammatory diseases of the respiratory and urinary tract; clinical trials have shown efficacy comparable to standard antibiotics for uncomplicated urinary tract infections in some studies, with the antimicrobial activity attributed primarily to the isothiocyanate constituents AITC, PEITC, and BITC.

Magnitude: Angocin (containing AITC alongside PEITC and BITC) shows clinical efficacy comparable to antibiotics for uncomplicated urinary tract infections in trials cited by Hoch et al. (2024). Individual AITC contribution is not separately quantified.

Low 🟩

Anti-Inflammatory Effects

AITC suppresses inflammatory mediators through NF-κB inhibition and JNK (c-Jun N-terminal kinase, a stress-activated protein kinase that promotes inflammation) pathway modulation, with reductions in TNF-alpha, IL-6, and nitric oxide production in cell-culture and animal models of inflammation. The mechanism is consistent across studies and is shared with other isothiocyanates, but no dedicated controlled human anti-inflammatory trials of AITC alone have been completed.

Magnitude: Not quantified in available studies.

Phase II Detoxification Enzyme Induction

AITC induces phase II detoxification enzymes — glutathione S-transferases, UDP-glucuronosyltransferases, NAD(P)H quinone oxidoreductase 1 (an enzyme that detoxifies quinones and protects against oxidative stress) — through Nrf2 pathway activation. This induction is well-documented in animal and cell-culture work and is consistent with the broader isothiocyanate class effect including dietary sulforaphane. Direct human induction data for AITC alone are limited, with most translational confidence coming from sulforaphane studies.

Magnitude: Not quantified in available studies.

Neuroprotection

AITC protects neuroblastoma cells from activated microglia-induced toxicity through attenuation of JNK/NF-κB/TNF-alpha signaling and increases nerve growth factor expression. A separate rodent study showed AITC attenuates oxidative stress and inflammation after traumatic brain injury through Nrf2/HO-1 (heme oxygenase-1, an antioxidant enzyme activated by Nrf2) and NF-κB modulation. The data are preclinical and limited; no human neuroprotection trials exist.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cardiac Longevity via TRPA1 Activation

A 2025 GeroScience study (Qian et al.) reported that long-term dietary AITC (15 mg/kg food, 6 months, in 18-month-old C57BL/6J mice) increased heart rate variability and parasympathetic nervous system index, decreased cardiac fibrosis and collagen I/III deposition, and normalized the E/A ratio (a measure of diastolic filling) without affecting systolic function. The proposed mechanism is TRPA1 activation in cardiac vagal afferents enhancing efferent vagal tone. This is a single rodent study; human translation is unproven.

Anti-Diabetic and Metabolic Effects

Preclinical studies report that AITC ameliorates insulin resistance through mitochondrial regulation and reduces oxidative and inflammatory stress in type 2 diabetic rats, supported mechanistically by Bhat et al. (2025) on glucosinolate-derived isothiocyanates as anti-diabetic candidates. However, the only randomized human crossover trial of mustard-derived AITC (Langeveld et al., 2017) found no thermogenic, substrate-oxidation, or metabolic effects at the maximum tolerable dose, sharply tempering enthusiasm for translation to humans.

Host-Defense Modulation in Bacterial Infection

Drosophila melanogaster experiments (Zimmermann et al., 2024; Daehn et al., 2026) tested whether dietary AITC enhances antimicrobial peptide expression and survival following oral bacterial infection. The findings were largely negative: AITC produced concentration-dependent decreases in female-fly survival (Zimmermann 2024) and frequently exacerbated mortality without consistent antimicrobial peptide induction under high-sucrose-diet conditions (Daehn 2026), with strongly sex-specific responses. These results temper enthusiasm for AITC as a host-defense priming agent and highlight the limits of extrapolating direct antimicrobial activity to host-protection benefits.

Anti-AGE/RAGE Activity

A 2024 review (Krisanits et al.) frames isothiocyanates including AITC as candidates for inhibiting advanced glycation end products and the receptor for advanced glycation end products (RAGE), implicated in chronic inflammation and aging. Direct AITC-specific anti-AGE/RAGE evidence is limited and the framing is mechanistic at this stage.

Antidepressant-Like Effects

Animal studies have reported antidepressant-like effects of AITC isolated from mustard oil through blocking the interaction between SERT (serotonin transporter, a protein that removes serotonin from the synaptic cleft) and nNOS (neuronal nitric oxide synthase, an enzyme that produces nitric oxide in nerve cells). This is very early-stage rodent research with no human data.

Benefit-Modifying Factors

Because AITC research is predominantly preclinical, human-specific benefit-modifying factors are mostly inferred from the broader isothiocyanate literature.

GSTM1 and GSTT1 polymorphisms: GSTM1 (glutathione S-transferase M1, an enzyme that conjugates and eliminates isothiocyanates) and GSTT1 (glutathione S-transferase T1, another enzyme involved in isothiocyanate metabolism) null genotypes result in slower clearance of isothiocyanates through the mercapturic acid pathway, potentially extending tissue exposure and biological effects. Documented for sulforaphane and likely applicable to AITC given shared metabolism.
Baseline oxidative stress and inflammatory burden: Individuals with elevated baseline oxidative stress or chronic low-grade inflammation may experience more pronounced relative benefit from Nrf2 activation and NF-κB suppression, given that Nrf2 activity itself declines with chronic stress and aging.
Sex-based differences: No sex-specific differential responses to AITC have been established in humans. The Qian et al. (2025) cardiac aging study used both male and female mice; no sex-specific divergence in cardiac outcomes was emphasized.
Age: Nrf2 activity and phase II enzyme expression decline with age, suggesting older individuals may derive greater relative benefit from Nrf2 activators. The cardiac longevity signal in mice was specifically observed in aged animals.
Pre-existing conditions and bladder cancer risk profile: Individuals at elevated bladder cancer risk (e.g., heavy smokers, those with occupational aromatic-amine exposure) may theoretically benefit most from AITC’s bladder-selective preclinical chemoprevention signal, but no clinical evidence supports this in humans.

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Irritation

AITC is the most pungent of the common dietary isothiocyanates, responsible for the burning sensation of mustard and wasabi. Higher dietary loads can cause stomach upset, nausea, and mucosal irritation through TRPA1 and TRPV1 (transient receptor potential vanilloid 1, a channel that detects heat and pungency) activation in gastrointestinal sensory nerves. The Langeveld et al. (2017) randomized controlled trial was constrained by maximum tolerable dose of mustard, indicating a practical tolerability ceiling for concentrated supplementation.

Magnitude: Dose-limited by tolerability. The Langeveld et al. (2017) trial used the maximum tolerable mustard dose (10 g of capsulated or uncapsulated mustard), which still produced no measurable thermogenic or metabolic effects.

Genotoxicity and Bladder Tumors at Very High Chronic Doses

The International Agency for Research on Cancer classifies AITC as Group 3 (not classifiable as to its carcinogenicity to humans). Lifetime rodent feeding studies with very high AITC doses (25–100 mg/kg/day for 2 years) caused urinary bladder papillomas and carcinomas in rats, likely through a non-genotoxic mechanism of sustained bladder epithelial irritation rather than direct DNA damage. At dietary exposure levels — orders of magnitude lower — genotoxic effects are considered unlikely, as discussed in Zhang (2010). Nonetheless, this finding is the principal regulatory basis for caution against high-dose concentrated AITC supplementation.

Magnitude: Bladder tumors in rats at 25–100 mg/kg/day over 2 years, mediated by chronic irritation. Dietary intake levels in humans are orders of magnitude below these thresholds.

Respiratory and Mucosal Irritation From Vapor

AITC vapor is a potent lacrimator and respiratory irritant via TRPA1 activation in trigeminal and olfactory neurons. Occupational and concentrated handling exposures can cause eye, nose, and throat irritation. Relevance to ordinary dietary intake is low, but it matters for handling concentrated mustard oils, freshly grated horseradish, or AITC fumigant preparations.

Magnitude: Olfactory detection threshold approximately 0.3 ppm in air. Occupational exposure limits have been established by California’s Department of Pesticide Regulation for fumigant use.

Speculative 🟨

Thyroid Disruption

Cruciferous-derived compounds have a theoretical thyroid-disrupting potential in iodine-deficient populations through goitrin generation, although clinical data for sulforaphane-rich preparations have not shown adverse thyroid effects over 12 weeks. No thyroid-specific human data exist for AITC alone.

Embryotoxicity and Pregnancy Caution

Some isothiocyanates show embryotoxic effects in animal models at high doses. AITC-specific embryotoxicity data are absent, but caution during pregnancy is prudent given the class effect, AITC’s high bioavailability, and its bladder-concentrating profile.

Exacerbation of Acute Parasitic Infection

A 2024 mouse study reported that AITC exacerbated acute toxoplasmosis through inhibition of inflammatory cytokines, suggesting that the same anti-inflammatory mechanism that supports chronic disease management could theoretically impair acute immune defense against certain intracellular parasites.

Allergic Reactions From Mustard Seed Sources

White mustard (Sinapis alba) and related species contain seed-storage proteins (Sin a 1, Sin a 2) implicated in allergic reactions. While this risk is tied to mustard products rather than purified AITC, individuals consuming concentrated mustard preparations should be aware, particularly in pediatric and atopic populations.

Risk-Modifying Factors

GSTM1-null and GSTT1-null genotypes: Slower mercapturic-acid pathway clearance can prolong both beneficial and adverse exposure to isothiocyanates including AITC.
Baseline biomarker levels: Elevated baseline hs-CRP (high-sensitivity C-reactive protein, a marker of systemic inflammation), abnormal urinalysis findings (e.g., microscopic hematuria), elevated GGT (gamma-glutamyl transferase, a sensitive marker of glutathione turnover and hepatobiliary stress), or impaired renal markers (creatinine, eGFR (estimated glomerular filtration rate, a measure of kidney filtration function)) at baseline can identify individuals at higher risk of adverse responses to concentrated AITC exposure, given AITC’s preferential bladder accumulation and impact on glutathione turnover.
Baseline kidney and bladder function: Given AITC’s preferential bladder accumulation and the rat bladder tumor finding at very high chronic doses, individuals with pre-existing bladder pathology, recurrent urinary tract irritation, or compromised kidney function should exercise additional caution with concentrated AITC supplementation.
Sex-based differences: No sex-specific risk data exist for AITC in humans.
Age: No specific age-related risk profile has been characterized for AITC. Older individuals with reduced clearance capacity could theoretically experience prolonged exposure, but this has not been studied.
Pre-existing conditions: Those with active gastritis, peptic ulcer disease, IBD (inflammatory bowel disease, a group of chronic conditions causing intestinal inflammation including Crohn’s disease and ulcerative colitis), interstitial cystitis (a chronic bladder pain syndrome with persistent urinary urgency and frequency), pregnancy, mustard or seed-protein allergy, or active acute parasitic or intracellular infections requiring a robust inflammatory response should exercise additional caution.

Key Interactions & Contraindications

CYP-substrate prescription drugs: AITC modulates phase I cytochrome P450 enzymes and phase II conjugating enzymes. Severity: caution. Consequence: altered metabolism of co-administered drugs with narrow therapeutic windows. Mitigation: avoid concentrated AITC supplementation in those on warfarin, immunosuppressants (cyclosporine, tacrolimus), or antiarrhythmics; consult a physician for dose review.
Anticoagulants and antiplatelet agents (e.g., warfarin, apixaban, clopidogrel): Cruciferous vegetable sources of AITC contain vitamin K, which can antagonize warfarin specifically. Severity: caution. Consequence: unstable INR (international normalized ratio, a measure of blood clotting time) with warfarin if cruciferous intake fluctuates substantially. Mitigation: maintain consistent cruciferous vegetable intake; INR monitoring during dietary changes.
NSAIDs (nonsteroidal anti-inflammatory drugs, e.g., ibuprofen, naproxen, aspirin) and selective COX-2 inhibitors (e.g., celecoxib): AITC has anti-inflammatory effects through NF-κB and COX-2 modulation. Severity: caution. Consequence: additive anti-inflammatory and gastric irritation effects; preclinical synergy with celecoxib for bladder cancer is documented but not clinically validated. Mitigation: monitor for GI (gastrointestinal) symptoms; do not exceed labeled NSAID dosing.
Antibiotics (broad-spectrum): The herbal preparation Angocin (AITC + PEITC + BITC) is used as an antimicrobial. Severity: monitor. Consequence: additive antimicrobial effect; possible alteration of pharmacodynamic response. Mitigation: clinician oversight for combined use, particularly for urinary tract indications.
Other Nrf2 activators and isothiocyanate-rich supplements (e.g., sulforaphane, broccoli sprout extract, curcumin, resveratrol): Severity: caution. Consequence: additive Nrf2 activation; theoretical risk of disrupting redox balance at high cumulative doses. Mitigation: avoid stacking concentrated isothiocyanate supplements.
Glutathione-depleting drugs (e.g., acetaminophen at high doses): Severity: caution. Consequence: depleted glutathione may slow AITC clearance through the mercapturic acid pathway. Mitigation: avoid concentrated AITC during acetaminophen overdose treatment or in active liver injury.
Populations who should avoid this intervention: Pregnant or breastfeeding women (avoid concentrated isothiocyanate supplements); individuals with active gastrointestinal inflammation or peptic ulcer disease; those with interstitial cystitis or other bladder pathology; individuals with documented mustard-seed protein allergy; patients with acute parasitic infection requiring robust inflammatory response; Child-Pugh Class C hepatic impairment (extrapolated from class effect of phase II enzyme modulation).

Risk Mitigation Strategies

Whole-food dietary sourcing: AITC obtained primarily through mustard (yellow, brown, and black varieties), freshly grated horseradish, wasabi, radish, and other cruciferous vegetables provides physiological exposure with established safety through centuries of culinary use, mitigating the bladder-tumor and tolerability concerns documented at concentrated doses.
Avoidance of high-dose concentrated AITC supplementation: Given rat bladder tumors at 25–100 mg/kg/day chronically, and the maximum tolerable mustard dose limit observed in the Langeveld et al. (2017) human RCT (randomized controlled trial), foregoing concentrated standalone AITC supplements outside of medically supervised herbal preparations such as Angocin mitigates both genotoxicity-at-high-dose and gastrointestinal (GI) tolerability risks.
Maximizing myrosinase activity through preparation: Raw or lightly steamed cruciferous vegetables, crushing or grating horseradish and allowing several minutes before consumption, and adding raw mustard seed powder to cooked dishes restore isothiocyanate yield, mitigating the risk of inert intake and the false expectation of a benefit when cooking has destroyed myrosinase.
Adequate iodine intake (~150 micrograms per day for adults): Sufficient dietary iodine mitigates the theoretical thyroid-disruption risk associated with chronic high cruciferous intake.
Gradual introduction of AITC-rich foods: Stepwise increases in mustard, horseradish, and wasabi consumption over weeks mitigate the risk of acute gastrointestinal irritation and support gastric and intestinal adaptation in individuals unaccustomed to pungent foods.
Well-ventilated handling of concentrated AITC and freshly grated horseradish: Reduces respiratory and mucosal irritation from AITC vapor exposure during food preparation.
Pausing concentrated AITC intake during acute parasitic or intracellular infection: Mitigates the speculative risk that AITC’s anti-inflammatory action could impair the acute inflammatory response needed for clearance of certain pathogens.

Therapeutic Protocol

No standardized therapeutic protocol exists for AITC as a standalone compound. No dedicated clinical trials have demonstrated efficacy for health outcomes, and the only randomized human trial (Langeveld et al., 2017) found no metabolic effects at the maximum tolerable mustard dose. The closest practitioner-validated approaches are dietary intake and the herbal preparation Angocin.

Dietary sources and content: Mustard seeds (yellow, brown, and black varieties) and horseradish are the richest dietary sources of sinigrin, the AITC precursor. Brown and black mustard contain higher sinigrin levels than yellow. Wasabi (most “wasabi” outside Japan is colored horseradish) is another concentrated source. Radish, Brussels sprouts, cabbage, and other cruciferous vegetables provide lower but consistent intakes.
Herbal medicinal preparation (Angocin Anti-Infekt N): Each tablet contains horseradish root 80 mg + nasturtium herb 200 mg, providing AITC alongside PEITC and BITC; authorized in Germany for inflammatory diseases of the upper respiratory and lower urinary tract. Typical dosing per the marketed preparation is 4–5 tablets three times daily, taken with meals to reduce GI irritation, used for short courses during infection.
Competing therapeutic approaches: Conventional approaches for the conditions where AITC has clinical signal (urinary tract infection, upper respiratory infection) center on antibiotics or symptomatic care; integrative approaches use AITC-containing botanicals as a complementary or first-line option for uncomplicated cases. Evidence for cancer chemoprevention or cardiac aging is preclinical only.
Best time of day: No specific time-of-day data exist for AITC. Taking with meals reduces GI irritation and may improve tolerability.
Half-life: AITC’s biological half-life is short (hours), with rapid absorption (~90% bioavailability) and rapid mercapturic-acid pathway metabolism; urinary metabolite excretion peaks within hours of dosing, consistent with short systemic exposure.
Single vs split dosing: Given the short half-life, split dosing (e.g., 2–3 times daily) is consistent with how Angocin is used clinically. For dietary intake, distribution across meals is the natural approach.
Genetic considerations: GSTM1-null and GSTT1-null individuals may experience prolonged isothiocyanate exposure due to slower mercapturic-acid pathway clearance.
Sex-based differences: No sex-specific dosing considerations for AITC have been established.
Age considerations: No age-specific therapeutic protocols exist. The Qian et al. (2025) cardiac aging study used 15 mg AITC/kg food for 6 months starting at 18 months of age in mice, which does not translate directly to a human dose.
Baseline biomarkers: No specific biomarker thresholds guide AITC use.
Pre-existing conditions: Individuals with active GI inflammation should avoid concentrated AITC sources. Those with bladder pathology should be cautious given AITC’s preferential bladder accumulation.

Discontinuation & Cycling

Duration of use: As a dietary component, AITC intake can be maintained indefinitely; centuries of culinary use establish chronic dietary exposure as safe. Concentrated herbal preparations (e.g., Angocin) are typically used in short courses tied to specific infections.
Withdrawal effects: None known. Discontinuation removes ongoing Nrf2 activation and anti-inflammatory signaling.
Tapering protocol: Not applicable for dietary sources; herbal preparations are stopped at end of clinical course without need for taper.
Cycling: No clinical evidence supports or contradicts cycling for maintaining AITC efficacy. Rodent data on long-term continuous intake (Qian et al., 2025) show no apparent loss of effect over 6 months, consistent with isothiocyanate class behavior.

Sourcing and Quality

Whole-food sources: Freshly grated horseradish root, freshly prepared mustard from intact seeds, true wasabi (Wasabia japonica) where available, and intact cruciferous vegetables prepared raw or lightly cooked provide the highest AITC yield. Most “wasabi” outside Japan is colored horseradish paste with mustard, and still contains AITC.
Herbal medicinal product: Angocin Anti-Infekt N (manufactured by Repha GmbH) is the principal standardized AITC-containing medicinal product with clinical data, available through European pharmacies and online retailers; pharmaceutical-grade manufacturing ensures consistency.
Standalone AITC supplements: No standalone AITC dietary supplements with pharmaceutical-grade quality controls are commercially marketed for health purposes. Synthetic AITC (mustard oil) is sold as a food flavoring and as a soil fumigant, neither of which is suitable for therapeutic use.
Freshness and volatility: AITC is volatile; prepared horseradish and wasabi pastes lose potency over time. Freshly grated horseradish root provides the highest AITC yield. Crushed mustard seeds should be used promptly to maximize sinigrin-to-AITC conversion through residual myrosinase before storage and oxidation diminish enzyme activity.
Third-party testing: For Angocin and similar pharmaceutical-grade botanicals, third-party verification is generally embedded in regulatory oversight; for dietary sources, organic produce reduces concomitant pesticide exposure but does not substantively change AITC content.

Practical Considerations

Time to effect: Nrf2-mediated phase II enzyme induction begins within hours in cell-culture systems. Clinical antimicrobial effects from Angocin appear over days during an acute infection course. The cardiac aging signal in mice required 6 months of dietary supplementation to manifest. In short, expected timelines depend heavily on the indication and remain largely undefined for human longevity outcomes.
Common pitfalls: Overcooking cruciferous vegetables destroys myrosinase and can collapse isothiocyanate yield; failing to chew or grate cruciferous foods sufficiently leaves sinigrin unhydrolyzed; expecting standalone “AITC supplements” to mirror the clinical evidence of Angocin overlooks the role of the multi-isothiocyanate herbal matrix in the existing data; conflating sulforaphane evidence with AITC-specific evidence overstates the human translational support for AITC.
Regulatory status: AITC has GRAS status from the U.S. Food and Drug Administration as a food flavoring agent. Synthetic AITC is also registered with the U.S. Environmental Protection Agency as a soil fumigant pesticide — a use unrelated to dietary consumption. Angocin Anti-Infekt N is authorized as an herbal medicinal product in Germany. No standalone AITC product holds pharmaceutical approval for a health outcome.
Cost and accessibility: Mustard, horseradish, and cruciferous vegetables are widely available at low cost. Angocin is accessible through European pharmacies and certain international online retailers, with monthly cost typically modest by prescription-medication standards. Fresh horseradish root remains the most potent low-cost natural source.

Interaction with Foundational Habits

Sleep: No direct effects of AITC on sleep architecture have been studied. The pungency of AITC-rich foods (mustard, horseradish, wasabi) consumed close to bedtime can cause GI discomfort or reflux in sensitive individuals, indirectly disrupting sleep — a practical consideration rather than a pharmacologic one. The cardiac vagal-tone signal from Qian et al. (2025) is theoretically supportive of parasympathetic nervous system function relevant to nighttime physiology, but no sleep-specific data exist.
Nutrition: AITC-rich foods contribute to dietary diversity. The “grate-and-wait” technique (crushing or grating cruciferous foods and letting them stand for several minutes before heating) maximizes sinigrin-to-AITC conversion through residual myrosinase activity. Adding raw mustard seed powder to cooked cruciferous dishes restores isothiocyanate yield after cooking inactivates plant myrosinase. Mustard seeds also provide protein, fiber, selenium, and omega-3 fatty acids; horseradish provides vitamin C, potassium, and fiber. The interaction direction is potentiating: nutrition practices directly determine how much active AITC is generated.
Exercise: No direct interaction between AITC and exercise has been formally studied. The TRPA1-mediated parasympathetic enhancement from the Qian et al. (2025) study could theoretically support heart-rate recovery after exercise (a parasympathetic-driven process), but this is mechanistic speculation. The interaction direction is none/speculative; no specific timing relative to workouts is supported.
Stress management: AITC’s anti-inflammatory NF-κB suppression supports the cellular component of stress response. The vagal-tone enhancement signal from TRPA1 activation, if it translates to humans, could provide an autonomic-balance mechanism complementary to behavioral stress-management practices such as breathwork or HRV (heart rate variability, a measure of beat-to-beat variation reflecting autonomic balance) biofeedback. The interaction direction is potentiating in mechanism, with no human data confirming additive effects.

Monitoring Protocol & Defining Success

Because AITC is consumed primarily through dietary sources with no established therapeutic protocol for health or longevity outcomes, formal monitoring is not standard practice. For individuals significantly increasing cruciferous and mustard-family intake or using Angocin under clinician supervision, the following monitoring framework reflects functional medicine practitioner guidance.

Baseline labs are typically obtained before intentionally increasing AITC-rich food intake or starting Angocin courses. Ongoing monitoring follows a cadence of 3–6 months for biomarker trends in habitual users, or at the end of a clinical course for short-term Angocin use.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation	High-sensitivity C-reactive protein. Conventional reference range: < 3.0 mg/L. Fasting not required. Best paired with ferritin to interpret
Urinalysis (with microscopy)	Normal, no hematuria	Monitors bladder health given AITC’s preferential bladder accumulation	Standard urinalysis. New hematuria or persistent irritative symptoms warrant urological workup. No fasting required
TSH	1.0–2.5 mIU/L	Monitors thyroid function with sustained increased cruciferous intake	Thyroid-stimulating hormone. Conventional reference range: 0.4–4.0 mIU/L. Morning draw preferred. Pair with free T3 and free T4 for full picture
GGT	10–30 U/L	Proxy for oxidative stress and hepatobiliary function	Gamma-glutamyl transferase. Conventional reference range: 5–65 U/L. Fasting preferred. Sensitive marker of glutathione turnover
CMP	Within optimal ranges	Tracks renal and hepatic function during chronic herbal-preparation use	Comprehensive metabolic panel, a basic chemistry profile. Includes creatinine, eGFR (estimated glomerular filtration rate), ALT (alanine aminotransferase, a liver enzyme), AST (aspartate aminotransferase, a liver enzyme). 12-hour fast preferred

Qualitative markers:
- Digestive comfort (most practical day-to-day indicator when increasing pungent food intake)
- Energy levels and subjective vitality
- Respiratory comfort and sinus clarity
- Frequency and severity of urinary tract symptoms in those using Angocin for recurrent UTI (urinary tract infection)
- General wellbeing and sleep quality

Emerging Research

Cardiac aging and TRPA1 activation: Qian et al., 2025 — long-term dietary AITC ameliorates cardiac fibrosis and diastolic dysfunction in aged C57BL/6J mice (n = aged cohort, 6-month exposure beginning at 18 months of age) through enhanced vagal tone, with proteomics implicating collagen metabolism and extracellular matrix-receptor interaction. TRPA1 knockout mice show accelerated cardiac aging, supporting a homeostatic role for the channel. Human translation requires dedicated clinical trials.
Glucosinolate-derived isothiocyanates and diabetes prevention: Bhat et al., 2025 — comprehensive review framing glucosinolate-derived isothiocyanates including AITC as candidates for diabetes prevention through Nrf2 activation, NF-κB inhibition, mitochondrial regulation via PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a master regulator of mitochondrial biogenesis), AMPK (AMP-activated protein kinase, a cellular energy sensor) regulation, downregulation of SREBP1 (sterol regulatory element-binding protein 1, a transcription factor that controls fatty acid and lipid synthesis), and TRPV1/TRPA1 modulation, while explicitly noting that current human evidence is constrained by source heterogeneity, dosage variability, and small samples — pointing to the need for standardized supplements in larger trials.
Anti-AGE/RAGE activity: Krisanits et al., 2024 — a Johns Hopkins-affiliated review proposing that the antioxidant and anti-inflammatory activities of isothiocyanates including AITC may temper the pathogenic effects of advanced glycation end products and the RAGE pathway, opening a new mechanistic frame for AITC in chronic-disease and aging contexts.
Innate immunity and host defense in infection: Daehn et al., 2026 and Zimmermann et al., 2024 — Drosophila models reporting that dietary AITC produced concentration-dependent decreases in female-fly survival, frequently exacerbated mortality under high-sucrose-diet conditions, and did not significantly induce antimicrobial peptide expression, with strongly sex-specific responses cautioning against extrapolating direct antimicrobial activity to host-protection benefits.
Phytotherapy for oral health: Brodzikowska et al., 2026 — narrative review reporting that white-mustard-derived AITC formulations reduce dental plaque indices and gingival bleeding in a 4-week double-blind trial, suppressing red-complex periopathogens, while emphasizing standardization and allergological screening before broader adoption.
Glucosinolate-derived anticancer agents: Joković et al., 2025 — review consolidating glucosinolate-derived isothiocyanates including AITC as anticancer candidates across tumor types, contextualizing the bladder-selective AITC profile within the broader class.
TRPA1 as a therapeutic target probe in humans: NCT07237022 — a recruiting observational study (started October 2025) characterizing the dermal vascular response to topical AITC, capsaicin, and cinnamaldehyde in 20 healthy volunteers (ages 18–45), conducted as foundational work toward investigating TRP channel signaling in diabetic peripheral neuropathy (DPN, nerve damage from diabetes). Other completed AITC-as-probe studies include NCT05354453 (Phase 1, BI 1839100 with AITC challenge, 104 healthy men) and NCT06809569 (Phase 1, laser speckle contrast imaging of AITC- and capsaicin-induced skin blood flow, 12 healthy male participants).
Future research directions that could weaken the case: Adequately powered human RCTs of standardized AITC for bladder cancer prevention have not been initiated; until they are, the rat-derived efficacy figures remain unconfirmed in humans. The absence of any thermogenic or metabolic effect at maximum tolerable mustard dose in Langeveld et al., 2017 signals that achieving therapeutic systemic concentrations may be impractical via dietary AITC alone. Human translation of the cardiac aging signal will require clinical trials specifically powered for diastolic function endpoints.

Conclusion

Allyl isothiocyanate is the most widely consumed dietary isothiocyanate, distinguished by very high oral absorption and a striking tendency to concentrate in the urinary bladder. This combination underwrites its strongest preclinical case — bladder-selective cancer chemoprevention — and is supported by consistent animal evidence and a coherent pharmacokinetic rationale. Its broad-spectrum antimicrobial activity has clinical translation through the German herbal preparation Angocin, where the multi-isothiocyanate botanical matrix has shown efficacy against uncomplicated urinary and respiratory tract infections. Anti-inflammatory and phase II detoxification effects are well-characterized in laboratory settings. A recent finding that long-term dietary intake of this compound ameliorates cardiac aging in mice by enhancing the activity of the parasympathetic nervous system has opened a new and intriguing dimension.

The dominant constraint is the absence of dedicated human trials for health outcomes. The single randomized controlled human study of mustard-derived allyl isothiocyanate found no metabolic effect at the maximum tolerable dose, illustrating both a tolerability ceiling and the difficulty of reaching therapeutic concentrations through dietary means. Bladder tumors observed in rats only at very high chronic doses define the upper limit of the safety window for concentrated supplementation, even though dietary exposures sit far below those thresholds.

For the longevity-oriented adult, allyl isothiocyanate is best understood as a well-supported dietary phytochemical with promising mechanistic and animal evidence across cancer, microbial, and now cardiac aging domains, but with human clinical validation still largely outstanding.

Top - Benefits - Risks - Protocol

AITC for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Bladder-Selective Cancer Chemoprevention

Antimicrobial Activity

Low 🟩

Anti-Inflammatory Effects

Phase II Detoxification Enzyme Induction

Neuroprotection

Speculative 🟨

Cardiac Longevity via TRPA1 Activation

Anti-Diabetic and Metabolic Effects

Host-Defense Modulation in Bacterial Infection

Anti-AGE/RAGE Activity

Antidepressant-Like Effects

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Irritation

Genotoxicity and Bladder Tumors at Very High Chronic Doses

Respiratory and Mucosal Irritation From Vapor

Speculative 🟨

Thyroid Disruption

Embryotoxicity and Pregnancy Caution

Exacerbation of Acute Parasitic Infection

Allergic Reactions From Mustard Seed Sources

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion